GE HealthCare delivered a positive second quarter, with revenue and non-GAAP profit both surpassing Wall Street’s expectations. The company’s performance was driven primarily by robust orders growth, especially in Pharmaceutical Diagnostics and Advanced Imaging Solutions. CEO Peter Arduini credited broad-based demand for GE HealthCare’s portfolio and highlighted the impact of new product launches and improvements in service businesses. The management team acknowledged ongoing challenges in Patient Care Solutions (PCS), noting operational fulfillment issues but emphasizing recent order momentum and ongoing improvement initiatives.
Is now the time to buy GEHC? Find out in our full research report (it’s free for active Edge members).
GE HealthCare (GEHC) Q2 CY2026 Highlights:
- Revenue: $5.30 billion vs analyst estimates of $5.27 billion (5.8% year-on-year growth, 0.5% beat)
- Adjusted EPS: $1.13 vs analyst estimates of $1.04 (9.1% beat)
- Management reiterated its full-year Adjusted EPS guidance of $4.90 at the midpoint
- Operating Margin: 14%, in line with the same quarter last year
- Organic Revenue rose 3.5% year on year (beat)
- Market Capitalization: $31.74 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From GE HealthCare’s Q2 Earnings Call
-
Larry Biegelsen (Wells Fargo): Asked about the sustainability of strong orders and the impact of U.S. capital equipment demand concerns. CEO Peter Arduini explained the orders were broad-based, driven by execution and enterprise accounts, with no one-time items, and indicated continued strength across procedure-driven businesses.
-
Vijay Kumar (Evercore ISI): Inquired about drivers behind Pharmaceutical Diagnostics growth and Flyrcado’s ramp. Arduini detailed broad-based strength in imaging agents and confirmed the $500 million annual target for Flyrcado by 2028, citing increased customer onboarding and utilization.
-
Rick Wise (Stifel): Sought insight on whether the innovation wave was translating to order growth and which products were main contributors. Arduini noted the current innovation cycle is beginning to impact results, but core products remain the largest driver, with new launches expected to contribute more in coming quarters.
-
Travis Steed (BofA Securities): Questioned inflation’s impact on margins and the timeline for PCS stabilization. CFO Jay Saccaro confirmed inflation was in line with expectations and highlighted cost and pricing actions to offset pressures, while Arduini stated PCS should recover as supply chain issues are resolved.
-
Joanne Wuensch (Citi): Probed on China’s market dynamics amid policy changes. Arduini reported China performance was in line with plans and that ongoing adjustments for value-based procurement and provincial government strategies are being managed through targeted product positioning and engagement.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be monitoring (1) the pace of PCS revenue and margin recovery as operational changes take effect; (2) adoption rates and revenue contribution from new imaging and diagnostic product launches, including Photonova Spectra and Flyrcado; and (3) execution of price and cost measures to offset inflation. Progress in the PCS strategic review and service contract growth will also be important to watch.
GE HealthCare currently trades at $70.17, up from $64.11 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
